ATG-207

ATG-207 is an investigational, orally bioavailable small molecule designed as a dual inhibitor of the Bromodomain and Extra-Terminal motif (BET) proteins and the Mitogen-activated protein kinase kinase (MEK). Developed by Antengene Corporation, the drug targets the synergistic intersection of epigenetic regulation and the MAPK/ERK signaling pathway. By inhibiting BET proteins, particularly BRD4, ATG-207 suppresses the expression of oncogenic drivers such as MYC. Simultaneously, its inhibition of MEK1/2 blocks downstream signaling in the RAS/RAF/MEK/ERK pathway, which is frequently dysregulated in various cancers. This dual-targeting approach is intended to enhance therapeutic efficacy and delay the emergence of resistance compared to monotherapies. It is currently being evaluated in preclinical models for the treatment of solid tumors and hematological malignancies.